Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea · Delayed Price · Currency is KRW 5,660.00
+60.00 (1.07%)
At close: Aug 7, 2025, 3:30 PM KST
CTI BioPharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2020 |
Net Income | 5,524 | 4,888 | 4,680 | 4,415 | -1,476 | 362.66 | Upgrade |
Depreciation & Amortization | 4,312 | 4,260 | 3,937 | 3,758 | 3,672 | 2,584 | Upgrade |
Loss (Gain) From Sale of Assets | -29.09 | -7 | 0 | -38.55 | -0.73 | -4,581 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | - | - | 18.16 | - | Upgrade |
Loss (Gain) From Sale of Investments | 323.41 | 323.41 | - | - | - | - | Upgrade |
Provision & Write-off of Bad Debts | 87.07 | 143.72 | -30.85 | -159.25 | 1.26 | -86 | Upgrade |
Other Operating Activities | 1,866 | 1,995 | 2,366 | 1,531 | -344.75 | 190.08 | Upgrade |
Change in Accounts Receivable | -2,457 | -2,597 | -2,201 | -2,373 | -659.54 | 1,797 | Upgrade |
Change in Inventory | -2,098 | -2,302 | -3,022 | -5,062 | 1,316 | 1,422 | Upgrade |
Change in Accounts Payable | -938.29 | 195.72 | 241.53 | 2,063 | -2,165 | 840.24 | Upgrade |
Change in Other Net Operating Assets | -764.57 | -956.49 | -2,042 | 1,327 | -337.92 | -663.75 | Upgrade |
Operating Cash Flow | 5,825 | 5,943 | 3,930 | 5,461 | 23.18 | 1,865 | Upgrade |
Operating Cash Flow Growth | 36.13% | 51.23% | -28.03% | 23453.48% | -98.76% | - | Upgrade |
Capital Expenditures | -1,261 | -1,505 | -5,011 | -907.13 | -2,682 | -11,969 | Upgrade |
Sale of Property, Plant & Equipment | 29.11 | 7 | - | 43.64 | 0.79 | 18,771 | Upgrade |
Sale (Purchase) of Intangibles | -10 | -10 | -16.11 | -94.65 | - | 106.77 | Upgrade |
Investment in Securities | -4,002 | -4,004 | -1,004 | -176.61 | -3.41 | -2,790 | Upgrade |
Other Investing Activities | -14.8 | -46 | -20 | -10 | 33 | 4,511 | Upgrade |
Investing Cash Flow | -5,258 | -5,557 | -6,051 | -1,145 | -2,652 | 8,630 | Upgrade |
Short-Term Debt Issued | - | 39,888 | 25,306 | 18,349 | 20,224 | 21,676 | Upgrade |
Long-Term Debt Issued | - | - | - | - | 3,000 | 8,763 | Upgrade |
Total Debt Issued | 40,328 | 39,888 | 25,306 | 18,349 | 23,224 | 30,439 | Upgrade |
Short-Term Debt Repaid | - | -35,397 | -20,958 | -19,275 | -17,421 | -26,510 | Upgrade |
Long-Term Debt Repaid | - | -3,790 | -3,434 | -1,899 | -4,914 | -12,591 | Upgrade |
Total Debt Repaid | -39,665 | -39,187 | -24,392 | -21,174 | -22,335 | -39,100 | Upgrade |
Net Debt Issued (Repaid) | 662.95 | 701.82 | 914.06 | -2,825 | 889.86 | -8,661 | Upgrade |
Dividends Paid | -910.23 | -910.23 | -758.53 | - | - | -424.77 | Upgrade |
Other Financing Activities | -0 | - | 70 | - | 35 | -0 | Upgrade |
Financing Cash Flow | -247.28 | -208.41 | 225.54 | -2,825 | 924.86 | -9,086 | Upgrade |
Foreign Exchange Rate Adjustments | 31.95 | 15.79 | 1.89 | -50.12 | -0.96 | -35.11 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | -0 | 0 | -0 | - | - | Upgrade |
Net Cash Flow | 351.43 | 193.4 | -1,894 | 1,441 | -1,705 | 1,374 | Upgrade |
Free Cash Flow | 4,564 | 4,439 | -1,081 | 4,553 | -2,659 | -10,104 | Upgrade |
Free Cash Flow Margin | 4.27% | 4.17% | -1.05% | 4.95% | -3.59% | -15.05% | Upgrade |
Free Cash Flow Per Share | 300.87 | 292.60 | -71.27 | 300.15 | -175.28 | -666.04 | Upgrade |
Cash Interest Paid | 1,889 | 1,956 | 1,987 | 1,406 | 948.55 | 1,210 | Upgrade |
Cash Income Tax Paid | 273.92 | 182.18 | -747.52 | -396.26 | 1,650 | -131.56 | Upgrade |
Levered Free Cash Flow | 2,077 | 1,950 | -3,157 | 3,362 | -2,642 | -4,699 | Upgrade |
Unlevered Free Cash Flow | 3,257 | 3,175 | -1,946 | 4,288 | -2,040 | -4,141 | Upgrade |
Change in Net Working Capital | 4,498 | 3,877 | 4,609 | 1,860 | 2,190 | -7,744 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.